G. Cserni, S. Bianchi, V. Vezzosi, R. Arisio, R. Bori, J. L. Peterse, A. Sapino, M. Drijkoningen, J. Kulka, V. Eusebi, M. P. Foschini, J. P. Bellocq, C. Marin, S. Thorstenson, I. Amendoeira, A. Reiner-Concin and T. Decker, “Sentinellymph Node Biopsy and Non-Sentinelnode Involvement in Special Type Breast Carcinomas with a Good Prognosis,” European Journal of Cancer, Vol. 43, No. 9, 2007, pp. 1407-1414. doi:10.1016/j.ejca.2007.04.004

has been cited by the following article:

• TITLE: The Association between Sentinel Lymph Node Metastasis and Ki-67 Labeling Index

  AUTHORS: Yu Koyama, Hiroshi Ichikawa, Jun Sakata, Eiko Sakata, Kumiko Tatsuda, Miki Hasegawa, Chie Toshikawa, Naoko Manba, Mayuko Ikarashi, Toshifumi Wakai

  KEYWORDS: Breast Cancer; Sentinel Lymph Node; Molecular Subtypes; Ki-67 Labeling Index

  JOURNAL NAME: Advances in Breast Cancer Research, Vol.2 No.3, June 24, 2013

  ABSTRACT: Background: The purpose of this study was to elucidate the association between sentinel lymph node (SLN) metastasis and Ki67 labeling index and to elucidate whether Ki-67 was useful or not for prediction of SLN metastasis in breast cancer. Methods: We identified 343 invasive breast cancer patients with sentinel lymph node biopsy (SLNB) from 2003 to 2012. The association between SLN status and clinicopathological features, molecular subtypes and Ki-67 labeling index were evaluated. Results: SLN metastasis was detected in 79 patients (23.0%). SLN metastasis was significantly associated with clinical T-stage (p = 0.0003), lymphovascular involvement (LVI) (p 0.0001). Ki-67 labeling index of primary tumor was significantly lower in SLN positive patients (p = 0.0331), and Ki-67 cut-off point of 7.5% was useful for dividing SLN positive from negative (p = 0.0197). Conclusion: Low value of Ki-67 labeling index, in addition to progression of clinical T-stage and presence of LVI, is significantly associated with SLN metastasis, and it seems to be useful to consider Ki-67 labeling index for SLN metastasis prediction.